Kolexia
Cornec Divi
Rhumatologie
Hôpital Cavale Blanche
Brest, France
489 Activités
1.1 K Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndrome de Gougerot-Sjögren Arthrite Polyarthrite rhumatoïde Vascularite Maladies auto-immunes Vascularites associées aux anticorps anti-cytoplasme des neutrophiles Rhumatisme inflammatoire des ceintures Inflammation Artérite à cellules géantes

Industries

Janssen
6 collaboration(s)
Dernière en 2022
Lilly
5 collaboration(s)
Dernière en 2023
Novartis
4 collaboration(s)
Dernière en 2022
Fresenius Kabi
2 collaboration(s)
Dernière en 2023

Dernières activités

Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis.
Rheumatology (Oxford, England)   01 mars 2024
Reply.
Arthritis & rheumatology (Hoboken, N.J.)   07 février 2024
Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group.
Seminars in arthritis and rheumatism   30 janvier 2024
CRI-RA: Combination of Baricitinib and Anti-TNF vs. Baricitinib in Patients With Rheumatoid Arthritis: a Randomized Placebo-controlled Phase III Trial
Essai Clinique (Biogen)   30 janvier 2024
"If I have Sjögren's syndrome, I want to know it as early as possible": The perspective of first-degree relatives of patients with Sjögren's syndrome from an international survey.
Joint bone spine   28 janvier 2024
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation.
Seminars in arthritis and rheumatism   23 janvier 2024
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial.
The Lancet. Rheumatology   22 janvier 2024
Presence of ectopic germinal center structures in autoimmune hepatitis.
Clinical immunology (Orlando, Fla.)   23 décembre 2023
Combined anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies are associated with increased Sjögren's disease severity through interferon pathway activation.
Arthritis & rheumatology (Hoboken, N.J.)   21 décembre 2023
High-content multimodal analysis supports the IL-7/IL-7 receptor axis as a relevant therapeutic target in primary Sjögren's syndrome.
Journal of autoimmunity   18 décembre 2023